| Literature DB >> 32513961 |
Daniel Trejo Banos1, Daniel L McCartney2, Marion Patxot3, Lucas Anchieri3, Thomas Battram4,5, Colette Christiansen6, Ricardo Costeira6, Rosie M Walker2, Stewart W Morris2, Archie Campbell2, Qian Zhang7, David J Porteous2, Allan F McRae7, Naomi R Wray7, Peter M Visscher7, Chris S Haley8, Kathryn L Evans2, Ian J Deary9,10, Andrew M McIntosh2,9,11, Gibran Hemani4,5, Jordana T Bell6, Riccardo E Marioni2,9, Matthew R Robinson12.
Abstract
Linking epigenetic marks to clinical outcomes improves insight into molecular processes, disease prediction, and therapeutic target identification. Here, a statistical approach is presented to infer the epigenetic architecture of complex disease, determine the variation captured by epigenetic effects, and estimate phenotype-epigenetic probe associations jointly. Implicitly adjusting for probe correlations, data structure (cell-count or relatedness), and single-nucleotide polymorphism (SNP) marker effects, improves association estimates and in 9,448 individuals, 75.7% (95% CI 71.70-79.3) of body mass index (BMI) variation and 45.6% (95% CI 37.3-51.9) of cigarette consumption variation was captured by whole blood methylation array data. Pathway-linked probes of blood cholesterol, lipid transport and sterol metabolism for BMI, and xenobiotic stimuli response for smoking, showed >1.5 times larger associations with >95% posterior inclusion probability. Prediction accuracy improved by 28.7% for BMI and 10.2% for smoking over a LASSO model, with age-, and tissue-specificity, implying associations are a phenotypic consequence rather than causal.Entities:
Mesh:
Substances:
Year: 2020 PMID: 32513961 PMCID: PMC7280277 DOI: 10.1038/s41467-020-16520-1
Source DB: PubMed Journal: Nat Commun ISSN: 2041-1723 Impact factor: 14.919